Skip to main content
PDSB
NASDAQ Life Sciences

PDS Biotechnology Regains Nasdaq Compliance, Eliminating Delisting Risk

Reported by Wiseek News
Sentiment info
Positive
Importance info
7
Price
$1.19
Mkt Cap
$66.421M
52W Low
$0.507
52W High
$1.915
Market data snapshot near publication time

Summary

PDS Biotechnology has officially regained compliance with Nasdaq's minimum $1.00 bid price requirement, removing the risk of delisting. This follows a deficiency notice issued on February 25, 2026, and an 8-K filing earlier today confirming the resolution. For a company of this size, maintaining Nasdaq listing is crucial for investor confidence and access to capital markets.

At the time of this announcement, PDSB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $0.51 to $1.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.

Price Chart

Share this article

Copied!

PDSB - Latest Insights

PDSB
Jun 02, 2026, 3:43 PM EDT
Source: Wiseek News
Importance Score:
7
PDS Biotechnology Regains Nasdaq Compliance, Eliminating Delisting Risk
Price at Filing: $1.19
Real-time Price: $1.12 info
Change: -$0.070 (-6%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
Jun 02, 2026, 3:35 PM EDT
Filing Type: 8-K
Importance Score:
8
PDS Biotech Regains Nasdaq Compliance, Resolving Delisting Threat
Price at Filing: $1.18
Real-time Price: $1.12 info
Change: -$0.055 (-5%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
May 13, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
PDS Biotechnology Beats Q1 EPS, Narrows Net Loss on Reduced Operating Costs
Price at Filing: $1.14
Real-time Price: $1.12 info
Change: -$0.020 (-2%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
May 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
PDS Biotech Reports Strong Q1, Exceptional mCRC Data, and Accelerated Approval Pathway for Phase 3 Trial
Price at Filing: $1.14
Real-time Price: $1.12 info
Change: -$0.020 (-2%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
May 01, 2026, 12:26 PM EDT
Filing Type: 8-K
Importance Score:
8
PDS Biotech Secures $5.76M Financing, Restructures Debt, and Launches New ATM Program
Price at Filing: $0.9706
Real-time Price: $1.12 info
Change: +$0.1494 (+15%) info
Market Cap: $62.514M info
Sentiment: Neutral
View Wiseek Article
PDSB
Apr 27, 2026, 11:51 AM EDT
Filing Type: S-3/A
Importance Score:
9
PDS Biotech Files $200M Universal Shelf Registration Following Positive Phase 2 Data
Price at Filing: $0.8982
Real-time Price: $1.12 info
Change: +$0.2218 (+25%) info
Market Cap: $62.514M info
Sentiment: Negative
View Wiseek Article
PDSB
Apr 15, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
PDS01ADC Shows 78% ORR, >80% 2-Year Survival in mCRC Phase 2 Trial, Data Published
Price at Filing: $1.08
Real-time Price: $1.12 info
Change: +$0.040 (+4%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
Mar 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
PDS Biotech Amends Phase 3 Trial for Accelerated Approval Pathway, Reports Encouraging Clinical Data
Price at Filing: $0.5696
Real-time Price: $1.12 info
Change: +$0.5504 (+97%) info
Market Cap: $62.514M info
Sentiment: Positive
View Wiseek Article
PDSB
Mar 30, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
PDS Biotechnology Reports Significant 74-Cent Per Share Loss for 2025
Price at Filing: $0.5696
Real-time Price: $1.12 info
Change: +$0.5504 (+97%) info
Market Cap: $62.514M info
Sentiment: Negative
View Wiseek Article
PDSB
Mar 03, 2026, 12:03 PM EST
Source: Wiseek News
Importance Score:
8
PDS Biotechnology Receives Nasdaq Deficiency Notice for Minimum Bid Price
Price at Filing: $0.6821
Real-time Price: $1.12 info
Change: +$0.4379 (+64%) info
Market Cap: $62.514M info
Sentiment: Negative
View Wiseek Article